| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lenvatinib |
| Brand | Lenvima® |
| Indication | For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine. |
| Assessment Process | |
| Rapid review commissioned | 05/05/2015 |
| Rapid review completed | 09/07/2015 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations. January 2016.
